At the forefront of this shift is Nuropod, a U.S.-available, non-invasive, ear-worn vagus nerve stimulation wearable designed to help support reductions in symptoms associated with persistent fatigue, ...

WEIFANG, SHANDONG, CHINA, January 21, 2026 /EINPresswire.com/ -- 1. Rising Global Demand for PDT LED Light Therapy As ...

The FDA has cleared a wearable device for adults with locally advanced pancreatic cancer that delivers low-intensity electric ...

For millions of Americans with essential tremor, simple tasks like writing a note, putting on makeup or plugging in an appliance can be difficult. | For millions of Americans with essential tremor, ...

Aktiia, makers of Hilo, the world's first clinically validated, cuffless, continuous blood pressure monitor for consumers, ...

The FDA has approved Optune Pax, a wearable medical device that delivers Tumor Treating Fields (TTFields), for the treatment of adult patients with locally advanced pancreatic cancer (LA-PAC) ...

The FDA has approved a first-of-its-kind wearable electrical device — Optune Pax (Novocure) — for patients with locally ...

Oura partners with femtech company Mira to integrate hormone testing data with wellness tracking, targeting the booming $60B ...

The FDA approved a tumor treating fields (TTFields) device for locally advanced pancreatic cancer, the first therapy approved in this setting in nearly 30 years.

Encora's device is set to be available in the US via a prescription-only model.

Encora Therapeutics announced today that it has received FDA 510(k) clearance for its Encora X1 wrist-worn device.

Optune Pax is a portable medical device that delivers TTFields non-invasively via wearable arrays to disrupt electrical processes essential for cancer cell division.